Relmada Therapeutics/$RLMD
1D1W1MYTD1Y5YMAX
Capital at risk
About Relmada Therapeutics
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
- Ticker
- $RLMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17
- Headquarters
- Coral Gables, United States
- Website
- www.relmada.com
RLMD Metrics
BasicAdvanced
$439M
-
-$0.85
0.49
-
Price and volume
Market cap
$439M
Beta
0.49
52-week high
$8.00
52-week low
$1.47
Average daily volume
1.3M
Financial strength
Current ratio
29.517
Quick ratio
29.342
Profitability
Management effectiveness
Return on assets (TTM)
-32.39%
Return on equity (TTM)
-55.66%
Valuation
Price to book
2.13
Price to tangible book (TTM)
2.13
Price to free cash flow (TTM)
-6.561
Free cash flow yield (TTM)
-15.24%
Free cash flow per share (TTM)
-0.628
Growth
Earnings per share change (TTM)
-61.36%
3-year earnings per share growth (CAGR)
-41.81%
What the Analysts think about RLMD
Analyst ratings (Buy, Hold, Sell) for Relmada Therapeutics stock.
Analyst projections of the future price of Relmada Therapeutics stock.
Bulls say / Bears say
NDV-01 generated encouraging 12-month Phase 2 interim results, including a 76% complete-response rate overall and 80% in BCG-unresponsive patients, with no Grade 3-or-higher treatment-related adverse events or treatment-related discontinuations reported. (Relmada Therapeutics)
Relmada reported $217.7 million in cash, cash equivalents and short-term investments as of June 30, 2026, which management expects to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program. (Relmada Therapeutics)
The pipeline offers multiple potential value drivers: NDV-01 is planned for two separate NMIBC indications, while sepranolone is targeted for Prader-Willi syndrome and other GABA-related disorders, with U.S. IND filings planned by year-end 2026. (SEC)
Relmada remains pre-revenue and loss-making: it reported a $32.0 million net loss and $24.7 million of operating cash burn for the six months ended June 30, 2026. (SEC)
The March 2026 $160.0 million PIPE materially increased the share count through 29.5 million new shares and 4.2 million pre-funded warrants, creating dilution for existing holders. (Relmada Therapeutics)
NDV-01 still faces substantial execution and regulatory risk: the company expects to file its U.S. IND by year-end 2026, with both Phase 3 programs dependent on FDA clearance, so pivotal development has not yet begun in the United States. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
RLMD Financial Performance
Revenues and expenses
RLMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
RLMD News
AllArticlesVideos
Funds containing RLMD
Fund name | Fund size | $RLMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.